Sepracor SEPR
-
Do Mergers Mean Billions for Biotech?
Michael Becker submits: In March 2009, we asked the question “ Where Might Genentech Investors Redeploy $47 Billion? ” in response to the news that Roche Holding AG ( RHHBY.PK ) would acquire the outstanding publicly held interest in Genentech for a total payment of approximately $47 billion in ...
-
An Improving Merger Environment?
… In healthcare , two deals at the top of the list - - Bristol - Meyers'bid for Medarex and Dianippon's ( Japan ) bid for Sepracor - - were both valued in excess of $ 2 billion . The other 5 transactions in the sector represented " tuck - in " acquisitions …
-
Dainippon Bids on Sepracor
… Sumitomo Pharma has offered to acquire Sepracor SEPR for about $2.6 billion, or ..... to our best-case scenario for Sepracor and represents a 44% premium to ..... presents a lucrative opportunity for Sepracor shareholders to cash out in a time …
-
Acquisition Rumors Lift Sepracor
… Dainippon Sumitomo Pharma may buy Sepracor SEPR for about $2.7 billion, or ..... to our base-case valuation. Sepracor has not commented on these rumors ..... as a surprise to us as we view Sepracor 's future drug portfolio with …
-
Strong 2Q for Sepracor
Sepracor SEPR reported strong second-quarter results ..... year. Lunesta sales drove this figure. Sepracor 's newer respiratory products also posted ..... respiratory growth as Xopenex goes off patent. Sepracor cut operating costs this quarter to …
-
Trial Setbacks for Sepracor
We are placing Sepracor SEPR under review as we reassess our long-term assumptions after news ..... led to the decision. The additional indication would have given Sepracor a six-month pediatric exclusivity extension on the Lunesta franchise …
-
DGTIX Delaware Trend Instl Fund Analysis, Report, Research, 5 Star Rating – Morningstar
… biotech and pharmaceutical holdings Medarex MEDX and Sepracor SEPR lost about 50% of their value last year but have started off 2009 with strong showings. Sepracor , which produces anti-insomnia drug Lunesta and respiratory …
-
DFDIX Delaware Growth Opportunities Instl Fund Analysis, Report, Research, 5 Star Rating – Morningstar
… example, only lost 16.3% and 4.1%, respectively. Not all picks were so lucky, though; drug manufacturer Sepracor SEPR shed 58% of its value over concerns about the company's ability to prosper as its main products, Lunesta and Xopenex …
-
Sepracor's 4Q In Line
Sepracor SEPR announced fourth-quarter results Wednesday ..... keeping our fair value estimate intact. Sepracor 's fourth-quarter revenue climbed 9 ..... significantly heading into 2009, with Sepracor expecting sales to fall roughly 7% for …
-
Valeant Partners Retigabine to GSK
… s terms are far superior to the recent deal struck by Portuguese firm Bial to license its anti-epilepsy drug to Sepracor SEPR , which agreed to pay an up-front payment of just $75 million and an additional $100 million if all milestones …